Why GlaxoSmithKline plc's Investment Plans Should Thrust Earnings Skywards The Motley Fool UK Indeed, the pharma giant announced recently that its MAGE-A3 immunotherapeutic drug for the treatment of lung cancer had failed Phase III testing at both the first and second co-primary endpoints. The trial for the revolutionary drug ... The company is ... |
